Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J
J Clin Oncol. 1987 Jan;5(1):21-6. doi: 10.1200/JCO.1987.5.1.21.
To determine the role of chemotherapy in the multidisciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastatic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose methotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the less than 20% disease-free or overall survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.
为确定化疗在骨肉瘤患者多学科治疗中的作用，1981年启动了一项术后辅助化疗的随机前瞻性试验。59例非转移性经典髓内骨肉瘤患者被随机分组；32例接受了由大剂量甲氨蝶呤、阿霉素（阿德里亚实验室，俄亥俄州哥伦布市）和BCD（博来霉素、环磷酰胺、放线菌素D）组成的术后辅助化疗，27例患者未接受辅助化疗。在中位随访2年时，接受辅助化疗的患者在无病生存期和总生存期方面均有统计学意义的改善。此外，与同期未治疗的对照组相比，20世纪70年代未接受化疗的患者无病生存期或总生存期低于20%，两者之间没有差异。因此，在相同的分期程序、统一的手术管理和标准的病理评估下，术后辅助化疗确实可改善骨肉瘤患者的无病生存期和总生存期。
